Clinical Trial Update: Effectiveness and Safety of Early Treatment With Infliximab for Hip Arthritis Associated With Ankylosing Spondylitis (AS) (P06451) [Phase 4]

View source ↗

Summary

The Phase 4 clinical trial evaluating early treatment with infliximab for hip arthritis associated with ankylosing spondylitis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis

Drugs mentioned

• Remicade (infliximab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Ankylosing Spondylitis | Phase 4 | Status: WITHDRAWN